projects with 3 customers new to Pharsight: Lupin Pharmaceuticals,
Seattle Genetics and NeurogesX
-- Expanded the RAS team with the addition of four scientific specialists.
-- Continued to expand the internship program with the first intern hire
within RAS.
-- Signed a $265,000 agreement with a global biotechnology company for
regulatory population pharmacokinetics and pharmacodynamic analysis and
reporting.
-- Achieved positive margin and strong revenue growth; RAS revenue grew
30% sequentially compared with the fiscal first quarter of 2008.
Other
-- Presented at the New York Pharma Forum on the FDA's Critical Path
Initiative.
-- Presented at the Noble Financial "Two-Double-O-Seven" financial
conference.
-- Applied for Nasdaq Capital Market listing status.
Additional Financial Results
Gross margin in the second quarter of fiscal 2008 was 67%. Net income attributable to common stockholders was $915,000 in the fiscal second quarter of 2008, up 71% compared with $534,000 in the comparable period of fiscal 2007. Net earnings per basic and diluted share were both $0.03 during the second quarter of fiscal 2008 compared with $0.03 and $0.02 respectively during the second fiscal quarter of 2007. Non-GAAP net earnings per basic and diluted share for the second quarter of fiscal 2008 were both $0.04 respectively compared with $0.04 and $0.03 respectively for the second quarter of fiscal 2007.
Revenue for the first six months of fiscal 2008 was $13.4 million, up
14% from $11.7 million reported for the same period of 2007. Gross margin
for the first six months of fiscal 2008 was 65%. GAAP net income for the
first six months of fiscal 2008 was $532,000, up 12% compared with the
comparable period of fiscal 2007. Excluding the impact of the adoption of
SFAS 123R, non-GAAP net
'/>"/>
| SOURCE Pharsight Corporation Copyright©2007 PR Newswire. All rights reserved |